EVerZom receives €3m funding from French government to industrialise exosome technology
Ella Day | June 18, 2025 | News story | Research and Development | BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease
EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of the France 2030 plan, through the ‘Biotherapies and Bioproduction of Innovative Therapies’ call for projects, operated by Bpifrance on behalf of the French government. This will support the industrialisation of its exosome bioproduction platform to develop and co-develop drug candidates.
With the funding, the company will scale-up its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch.
The support “is a strong recognition of [the company’s] technology and industrial ambition,” commented Jeanne Volatron, CEO of EVerZom. “We will secure a robust and scalable bioproduction process.”
The France 2030 plan is a governmental initiative using €54bn to support outstanding innovations and the emergence of technology champions in strategic sectors such as biotechnology, in alignment with economical initiatives relating to decarbonisation and sustainability. Bpifrance supports the growth of French businesses through financial and advisory services.
EVerZom leverages exosomes, key in intercellular communication, derived from mesenchymal stem cells, which are renowned for their regenerative and immunomodulatory properties. The programme has potential applications in a number of fields, including neurodegenerative diseases and age-related disorders. Its first candidate is intended to treat Crohn’s disease.
Ella Day
18/6/25
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
